Browse our latest Cancer Biology articles

Targeting the CRL5 ubiquitin ligase complex in combination with CDK9 or MCL1 inhibition could combat innate and acquired resistance of cancer cells to MCL1-targeting therapeutics.

P2ry12-mediated microglial interactions stimulate the proliferation of brain tumour initiating cells.

Natural activity of the antimicrobial peptide Defensin includes execution of tumour cell death by tumour necrosis factor in Drosophila.

Identification of the R(+)-propranolol enantiomer as an inhibitor of the SOX18 transcription factor activity breaks open potential of drug repurposing in vascular diseases.

Specific molecular links that orchestrate growth signals and metabolic reprogramming to achieve tumorigenesis are identified as potential metabolic vulnerabilities in cancer treatment.

Airway cells are required for the maintenance of the adult mouse lung and for carcinogen-induced lung adenocarcinoma development, and are thus marked therapeutic targets.

TP63 regulates NRG1 in squamous cell cancers, and targeting of NRG1 induces cancer cell differentiation thereby NRG1 is a potential therapeutic target in squamous cell cancers.

Pharmacologic inhibition of DNA methylation restrains the growth of urothelial carcinoma by subtype conversion through heightened stromal Hedgehog pathway activity.

Both VEGF-C and VEGF-D can be activated by KLK3/PSA and Cathepsin D, producing two novel VEGF-C forms and the known VEGFR-2-specific form of VEGF-D.

By increasing intracellular cysteine levels, NRF2 engages a tumor suppressive metabolic pathway mediated by cysteine dioxygenase 1.